

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Review of TA257; Breast cancer (first-line treatment of metastatic hormone-receptor positive) - lapatinib and trastuzumab (in combination with an aromatase inhibitor)

Final recommendation post consultation
TA257 will be transferred to the 'static guidance' list.

1. Background

This guidance was issued in June 2012.

At the GE meeting of 16 June 2015 it was agreed that we would consult on the recommendations made in the GE proposal paper. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

2. Proposal put to consultees and commentators

TA257 should be transferred to the 'static guidance' list.

3. Rationale for selecting this proposal

No new evidence has been found that would be expected to change the recommendations in TA257.

A subcutaneous version of trastuzumab is available, but it is not anticipated that this formulation would be significantly more cost effective than the intravenous version.

4. Summary of consultee and commentator responses

Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

<p>Respondent: Novartis Pharmaceuticals</p> <p>Response to proposal: Agree</p> <p>Novartis agrees that the guidance should be moved to the static list as there is no new evidence that would change the conclusions in the current guidance.</p>	<p>Comment from Technology Appraisals</p> <p>Response noted.</p>
<p>Respondent: Royal College of Pathologists</p> <p>Response to proposal: No comment</p>	<p>Comment from Technology Appraisals</p> <p>Response noted.</p>
<p>Respondent: Roche Products</p> <p>Response to proposal: Agree</p> <p>We have nothing further to add from our original response on 7th April 2015. We acknowledge the movement of TA257 to the static list and agree that at the time of update to the clinical guideline for Advanced breast cancer: Diagnosis and treatment (CG81), or any other relevant clinical guideline, that it would be appropriate to include the recommendations made in TA257.</p>	<p>Comment from Technology Appraisals</p> <p>Response noted.</p>

Paper signed off by: Janet Robertson, 28 July 2015

Contributors to this paper:

Technical Lead: Ahmed Elsada

Project Manager: Andrew Kenyon